Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders

NCT06797284 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-02-01
Last updated
2025-02-14

Condition(s) studied

Insomnia ChronicNarcolepsyREM Sleep Behavior Disorder

Investigational drug(s) / intervention(s)

Transcranial Magnetic Stimulation

Transcranial Magnetic Stimulation: repetitive transcranial magnetic stimulation, or transcranial direct current stimulation, or daytime timed bright light exposure

Study summary

Carry out precise and effective neuromodulation interventions, and develop new neuromodulation technologies for sleep disorders. Use phototherapy, transcranial electrical/magnetic stimulation and other therapies to conduct self-controlled intervention studies on insomnia, narcolepsy, and rapid eye movement sleep behavior disorder .

Eligibility

Sex
ALL
Min age
8 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: \- Patients with insomnia, narcolepsy,and RBD that have been clearly diagnosed by specialists should sign the informed consent form. Exclusion Criteria: 1. Patients with major neurological diseases such as multi-infarct dementia, Huntington\'s disease, normal pressure hydrocephalus, brain tumors, progressive supranuclear palsy, epilepsy, subdural hematoma, multiple sclerosis, or those who have sustained neurological dysfunction or known structural brain abnormalities after significant head trauma are excluded. 2. A history of major depressive disorder or bipolar disorder within the past year, as defined in DSM-IV criteria. A history of schizophrenia (meeting DSM-IV criteria). 3. History of severe drug or alcohol abuse within the past year; 4. Any significant systemic illness or unstable medical condition that may make it difficult to comply with the protocol, such as severe autoimmune diseases or a history of cancer. 5. Have significant hearing, visual, or cognitive impairments, or are unable to participate in interviews in a meaningful way.

Primary outcome measure(s)

  • Objective sleep indicators and clinical sleep-related scales — From enrollment to the end of treatment at 4 weeks

Trial sites (1)

FacilityCityRegionStatus
Department of Neurology, Second Affiliated Hospital of Soochow University Suzhou Jiangsu Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06797284 on ClinicalTrials.gov ↗ ← All trials in China